Practical implementation of a q4-q16 aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: Updated guidance from a UK expert panel.
Clare BaileyPeter CackettAjay KotagiriSajjad MahmoodEvangelos MinosNirodhini NarendranAshish PatwardhanDawn A SimPeter Morgan-WarrenCarolyn O'NeilKatie StrawPublished in: Eye (London, England) (2022)
The revised IVT-AFL T&E nAMD pathway offers guidance to clinicians seeking to increase the dosing flexibility of IVT-AFL, with 4- to 16-week treatment intervals, in line with the updated IVT-AFL label, to meet the continually evolving demands of nAMD service provision.